In short
Corifollitropin alfa, also known by the brand name Elonva, is a long-acting follicle-stimulating hormone (FSH) used in fertility treatments. This article explores various clinical trials investigating the use of corifollitropin alfa in controlled ovarian stimulation for in vitro fertilization (IVF) and other assisted reproductive technologies. These studies aim to optimize treatment protocols, improve outcomes, and enhance patient experiences in fertility treatments.
At a glance
- Primary Use
- Controlled ovarian stimulation for IVF and other assisted reproductive technologies
- Administration
- Single injection, sustaining follicle development for up to 7 days
- Key Benefits
- Reduced injection burden, sustained follicle development, potential for improved treatment scheduling
- Patient Populations Studied
- Expected normal responders, poor responders, high responders, PCOS patients
- Areas of Investigation
- Optimal timing of administration, comparison with daily FSH, efficacy in different patient groups, impact on embryo development and pregnancy rates
- Safety Considerations
- Risk of OHSS, especially in high responders; strategies to minimize risk being studied
- Outcome Measures
- Number of oocytes retrieved, embryo quality, pregnancy rates, patient satisfaction, pharmacokinetics
What is Corifollitropin Alfa?
Corifollitropin alfa, also known by its brand name Elonva, is a medication used in fertility treatments. It belongs to a class of drugs called gonadotropins, which are hormones that stimulate the ovaries or testes. Corifollitropin alfa is a long-acting form of follicle-stimulating hormone (FSH), designed to provide sustained stimulation of the ovaries for seven days with a single injection.
How Does It Work?
Corifollitropin alfa works by stimulating the ovaries to produce multiple follicles (small sacs containing eggs) during a single menstrual cycle. This process is known as controlled ovarian stimulation. By producing multiple follicles, the chances of obtaining viable eggs for in vitro fertilization (IVF) procedures are increased.
Unlike traditional FSH medications that require daily injections, corifollitropin alfa provides a sustained effect for an entire week with just one injection. This can significantly reduce the number of injections needed during fertility treatment.
Conditions Treated
Corifollitropin alfa is primarily used in the treatment of: Female Infertility: It is used as part of assisted reproductive technology (ART) programs, particularly for in vitro fertilization (IVF). Polycystic Ovary Syndrome (PCOS): Some studies have explored its use in women with PCOS undergoing IVF treatment. Male Hypogonadotropic Hypogonadism (HH): In combination with human chorionic gonadotropin (hCG), it has been studied for inducing testicular growth and sperm production in men with this condition.
Administration
Corifollitropin alfa is typically administered as follows: Single Injection: A single subcutaneous (under the skin) injection is given at the start of the ovarian stimulation cycle. Dosage: The dose is usually based on body weight. Women weighing 60 kg or less typically receive 100 μg, while those weighing more than 60 kg receive 150 μg. Timing: The injection is usually given on day 2 or 3 of the menstrual cycle, although some studies have explored starting on day 4 or even in the luteal phase (second half) of the cycle. Follow-up Treatment: After 7 days, if needed, daily injections of recombinant FSH may be given until the final day of stimulation.
Effectiveness
Studies have shown that corifollitropin alfa is effective in stimulating multiple follicle development. Its effectiveness has been compared to daily recombinant FSH injections in various patient groups: Normal Responders: In women expected to have a normal ovarian response, corifollitropin alfa has shown similar effectiveness to daily FSH injections. Poor Responders: Some studies have investigated its use in women who typically have a poor response to ovarian stimulation. High Responders: Its use has also been studied in women expected to have a high ovarian response. The primary measure of effectiveness is often the number of oocytes (eggs) retrieved after stimulation.
Side Effects
Like all medications, corifollitropin alfa can cause side effects. The most significant potential side effect is Ovarian Hyperstimulation Syndrome (OHSS), a condition where the ovaries become swollen and painful. Symptoms of OHSS can include abdominal pain, bloating, nausea, and in severe cases, shortness of breath.
Other potential side effects may include: Pelvic pain Headache Mood swings Nausea Tiredness Breast pain
Special Considerations
Several important points should be considered when using corifollitropin alfa: Monitoring: Regular monitoring of ovarian response through ultrasound and blood tests is crucial during treatment. Combination with Other Medications: Corifollitropin alfa is often used in combination with other fertility medications, such as GnRH antagonists, to prevent premature ovulation. Embryo Cryopreservation: In some cases, especially for patients at high risk of OHSS, all embryos may be frozen (cryopreserved) and transferred in a subsequent cycle. Patient Satisfaction: Some studies have suggested that patients may prefer corifollitropin alfa due to the reduced number of injections required. Ongoing Research: Studies are ongoing to further understand the optimal use of corifollitropin alfa in different patient populations and treatment protocols.